The value of tumor mutational burden to select patients for immunotherapy
نویسندگان
چکیده
منابع مشابه
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had un...
متن کاملEstimation of the Domain of Attraction of Free Tumor Equilibrium Point for Perturbed Tumor Immunotherapy Model
In this paper, we are going to estimate the domain of attraction of tumor-free equilibrium points in a perturbed cancer tumor model describing the tumor-immune system competition dynamics. The proposed method is based on an optimization problem solution for a chosen Lyapunov function that can be casted in terms of Linear Matrix Inequalities constraint and Taylor expansion of nonlinear terms. We...
متن کاملBiomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker in early clinical trials, but many shortcomings of ...
متن کاملconditional copula-garch methods for value at risk of portfolio: the case of tehran stock exchange market
ارزش در معرض ریسک یکی از مهمترین معیارهای اندازه گیری ریسک در بنگاه های اقتصادی می باشد. برآورد دقیق ارزش در معرض ریسک موضوع بسیارمهمی می باشد و انحراف از آن می تواند موجب ورشکستگی و یا عدم تخصیص بهینه منابع یک بنگاه گردد. هدف اصلی این مطالعه بررسی کارایی روش copula-garch شرطی در برآورد ارزش در معرض ریسک پرتفویی متشکل از دو سهام می باشد و ارزش در معرض ریسک بدست آمده با روشهای سنتی برآورد ارزش د...
O 25: Immunotherapy for Brain Tumor
In 1890, Coley observed that cancer patients who developed infections had smaller tumors. From this, he developed Coley’s toxin and treated tumors with injections of infectious materials. In 1960s, Mahaley used monoclonal antibodies to treat central nervous system(CNS) tumors, that research and clinical investigations in brain tumor immunotherapy became a serious undertaking. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Anticancer Therapy
سال: 2020
ISSN: 1473-7140,1744-8328
DOI: 10.1080/14737140.2020.1831386